Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2025 / July / CAM: Rethinking Regeneration in Ocular Surface Disease / Notecards
Anterior Segment Opinions Insights

CAM: Rethinking Regeneration in Ocular Surface Disease

Hardeep Kataria investigates the current and potential future uses of cryopreserved amniotic membrane in ocular surface disease therapy

By Hardeep Kataria 7/31/2025 4 min read

Share

article Full Article subject Summary summarize Notecard
  • AMT aids in ocular surface disease management.

  • Used since the 1940s, its applications have expanded.

  • Contains critical components like HC-HA/PTX3.

  • Effective in treating DED and corneal ulcers.

  • CAM enhances epithelial health before cataract surgeries.

  • Potential future applications include nerve regeneration.

  • The "sandwich method" combines CAM with nerve growth factors for acute conditions.

  • Continual research is expected to unlock further applications of AMT.

About the Author(s)

Hardeep Kataria

Hardeep Kataria is the founder of Avant Eyes Optometry & Advanced Dry Eye Center in Los Angeles, CA. Dr. Kataria reports affiliations with: BioTissue Ocular Inc, Dompé Farmaceutici, Alcon Vision, Sight Sciences, Viatris & Tarsus.

More Articles by Hardeep Kataria

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: